Amrita Krishnan, MD

Articles

Dr Krishnan on the Optimal Use of DKd in Relapsed/Refractory Multiple Myeloma

October 11th 2024

Amrita Krishnan, MD, discusses the role of DKd for patients with relapsed/refractory multiple myeloma.

Dr Krishnan on Maintenance Approaches in Transplant-Ineligible Multiple Myeloma

August 29th 2024

Amrita Krishnan, MD, discusses maintenance therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma.

Dr Krishnan on the Role of Cilta-Cel in High-Risk Multiple Myeloma

August 23rd 2024

Amrita Krishnan, MD, discusses the potential role for cilta-cel in early-relapsed, high-risk patients with multiple myeloma.

Dr Krishnan on the Evolving Role of Belantamab Mafodotin in Multiple Myeloma

August 12th 2024

Amrita Krishnan, MD, discusses the evolving role of belantamab mafodotin in the treatment of multiple myeloma.

Dr Krishnan on Patient Characteristics Associated With Early Relapse in Multiple Myeloma

July 11th 2024

Amrita Krishnan, MD, discusses the characteristics and factors associated with a higher risk of early relapse for patients with multiple myeloma.

Treatment Considerations and Sequencing in Multiple Myeloma

February 19th 2024

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

February 19th 2024

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

GPRC5D-Targeting Bispecifics in Multiple Myeloma

February 12th 2024

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.

Adverse Effects Related to Bispecifics in Multiple Myeloma

February 12th 2024

Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.

Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

February 5th 2024

Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.

Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

February 5th 2024

Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.

Updates on BCMA-Targeting Bispecifics in MM

January 29th 2024

An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.

Potential Role for CAR T-Cell Therapy in MM at Early Relapse

January 29th 2024

Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.

Treatment of Multiple Myeloma at Early Relapse

January 22nd 2024

A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.

The Evolving Treatment Paradigm for Transplant Ineligible MM

January 22nd 2024

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

Role of Transplant and MRD in Newly Diagnosed MM

January 15th 2024

Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.

Advances in the Treatment of High-Risk MM

January 15th 2024

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.

Highlights from ASH 2023 in Transplant-Eligible NDMM

January 15th 2024

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.

The Evolving Landscape of Newly Diagnosed Multiple Myeloma

December 14th 2023

A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.

Unmet Needs and Future Perspectives in Multiple Myeloma Care

March 13th 2023

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.